A new study (phase 3 ARIEL4 trial) to evaluate rucaparib (PARP Inhibitor) versus standard-of-care chemotherapy among patients with relapsed BRCA-mutated ovarian cancer showed median overall survival in the rucaparib group was 19.4 months versus 25.4 months in the chemotherapy group. This shows that more research is needed to figure out the most appropriate treatment options for patients who progressed on a PARP inhibitor.
Learn more at: https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00674-0/abstract
Reference: Oza et al. Lancet Oncol. 2025;26(2):249-264. PMID: 39914419.